Entrada Therapeutics, Inc. (TRDA)
NASDAQ: TRDA · IEX Real-Time Price · USD
12.36
-0.07 (-0.56%)
Apr 25, 2024, 4:00 PM EDT - Market closed

Entrada Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Year Current202320222021
Market Capitalization
415504425534
Market Cap Growth
-18.58%-20.54%-
Enterprise Value
128216258243
PE Ratio
-75.32-75.32-4.49-10.44
PS Ratio
3.223.90--
PB Ratio
1.722.082.001.79
P/FCF Ratio
3.103.75-4.39-9.64
P/OCF Ratio
2.983.60-4.53-10.51
EV/Sales Ratio
0.991.67--
EV/EBITDA Ratio
8.6114.49-2.78-4.86
EV/EBIT Ratio
10.6417.90-2.73-4.75
EV/FCF Ratio
0.961.61-2.67-4.39
Debt / Equity Ratio
0.280.280.12-
Debt / EBITDA Ratio
4.584.58-0.28-
Debt / FCF Ratio
0.510.51-0.27-
Quick Ratio
2.282.288.7743.32
Current Ratio
2.332.339.5544.46
Asset Turnover
0.270.2700
Return on Equity (ROE)
-2.90%-2.90%-38.70%-39.80%
Return on Assets (ROA)
-1.40%-1.40%-33.20%-29.30%
Return on Capital (ROIC)
0.56%0.56%-40.78%-17.12%
Earnings Yield
-1.61%-1.33%-22.28%-9.57%
FCF Yield
32.26%26.65%-22.77%-10.38%
Buyback Yield / Dilution
-5.61%-5.61%-399.27%-467.09%
Total Shareholder Return
-5.61%-5.61%-399.27%-467.09%
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).